Onlikang announced that the company and its subsidiary Haixi Pharmaceutical participated in the 12th batch of centralized procurement tenders for national drugs. The company plans to select sitagliptin metformin extended-release tablets, sacubatrol valsartan sodium tablets, and Haixi Pharmaceutical's inhaled heptafluorane. The procurement period is until December 31, 2029. The total sales volume of the three products to be selected in 2025 was approximately RMB 50.68 million, accounting for 3.56% of the company's total revenue for the year. If a purchase and sale agreement is signed and implemented later, it will have a positive impact on the company's operations, but the relevant procurement agreement has not yet been signed, and there is still uncertainty.

Onlikang announced that the company and its subsidiary Haixi Pharmaceutical participated in the 12th batch of centralized procurement tenders for national drugs. The company plans to select sitagliptin metformin extended-release tablets, sacubatrol valsartan sodium tablets, and Haixi Pharmaceutical's inhaled heptafluorane. The procurement period is until December 31, 2029. The total sales volume of the three products to be selected in 2025 was approximately RMB 50.68 million, accounting for 3.56% of the company's total revenue for the year. If a purchase and sale agreement is signed and implemented later, it will have a positive impact on the company's operations, but the relevant procurement agreement has not yet been signed, and there is still uncertainty.